Aurobindo Pharma FY26 Annual Earnings Summary

Generic Revlimid sales have largely been exhausted, with minimal future contribution expected, impacting U.S. revenue.

FDA reinspection for UGF3 facility is pending; timeline is uncertain (up to 8 months from September 2025), delaying injectable product launches.

Despite procedural observations, the USFDA decision on the warning letter is pending; management is cautiously optimistic but cannot predict outcome.

API revenue declined 16% YoY due to pricing pressure from both domestic and import competition, which may persist.

The Lannett acquisition is subject to FTC approval, which could take 8-12 months or longer, delaying synergies.

Potential U.S. tariffs and push for domestic manufacturing could increase costs and alter competitive dynamics.

Minimum import price (MIP) representation to government is pending; if delayed or denied, Pen-G ramp-up and profitability may be impacted.

New FDA draft guidance may lower entry barriers, increasing competition; Aurobindo may be third or later entrant in key products like denosumab.

H1 CapEx at INR 1,500 crore; ongoing investments in biosimilars, biologics CMO, and Pen-G may pressure cash flows despite unutilized capacities.

6-APA prices have been below cost of manufacture internationally, causing losses; correction expected by April but timing uncertain.

FTC approval process is ongoing; any delay or unexpected conditions could impact the timeline and synergies.

EBITDA burn from ramping up facilities like Pen G, Dayton, Raleigh, and biosimilars may pressure near-term margins.